{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:42:47Z","timestamp":1792636967935,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0900900"],"award-info":[{"award-number":["2018YFA0900900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473330"],"award-info":[{"award-number":["82473330"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["BE2021629"],"award-info":[{"award-number":["BE2021629"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007166","name":"Jiangsu Provincial Department of Education","doi-asserted-by":"publisher","award":["21KJA320009"],"award-info":[{"award-number":["21KJA320009"]}],"id":[{"id":"10.13039\/501100007166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ymthe.2025.03.024","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T18:00:44Z","timestamp":1742493644000},"page":"3339-3359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC"],"prefix":"10.1016","volume":"33","author":[{"given":"Ranran","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liechi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6020-7263","authenticated-orcid":false,"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.024_bib1","first-page":"229","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2025.03.024_bib2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2025.03.024_bib3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.024_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds187","article-title":"Triple-negative breast cancer: Epidemiological considerations and recommendations","volume":"23","author":"Boyle","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.03.024_bib7","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1002\/cncr.27581","article-title":"Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib11","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: Phase ib keynote-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13058-015-0621-0","article-title":"Human breast cancer cells educate macrophages toward the m2 activation status","volume":"17","author":"Sousa","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.12659\/MSM.895386","article-title":"Expression of tumor-related macrophages and cytokines after surgery of triple-negative breast cancer patients and its implications","volume":"22","author":"Wang","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ymthe.2025.03.024_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: From mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.03.024_bib16","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.024_bib17","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","article-title":"Macrophages at the interface of the co-evolving cancer ecosystem","volume":"186","author":"Kloosterman","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.024_bib18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","article-title":"Progress in tumor-associated macrophage (tam)-targeted therapeutics","volume":"114","author":"Ngambenjawong","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2025.03.024_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202002054","article-title":"Engineering macrophages for cancer immunotherapy and drug delivery","volume":"32","author":"Xia","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2025.03.024_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jconrel.2015.12.014","article-title":"Drug delivery to macrophages: Challenges and opportunities","volume":"240","author":"Pei","year":"2016","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2025.03.024_bib21","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1021\/acs.nanolett.1c01210","article-title":"Detachable liposomes combined immunochemotherapy for enhanced triple-negative breast cancer treatment through reprogramming of tumor-associated macrophages","volume":"21","author":"Chen","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2025.03.024_bib22","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41467-020-18626-y","article-title":"Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis","volume":"11","author":"Rao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.024_bib23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41467-020-20723-x","article-title":"Boosting anti-pd-1 therapy with metformin-loaded macrophage-derived microparticles","volume":"12","author":"Wei","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.024_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib25","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.03.024_bib26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and t cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.024_bib27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables t cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.024_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived cxcl9 and cxcl10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib29","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the cxcr3 chemokine system is required for the efficacy of anti-pd-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.03.024_bib30","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1158\/1078-0432.CCR-21-3215","article-title":"Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in basal-like triple-negative breast cancer","volume":"28","author":"Blenman","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib31","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of parp inhibitor olaparib, and pd-l1 inhibitor durvalumab, in recurrent ovarian cancer: A proof-of-concept phase ii study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12943-024-01970-8","article-title":"An international phase ii trial and immune profiling of sbrt and atezolizumab in advanced pretreated colorectal cancer","volume":"23","author":"Levy","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib33","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"Cxcl9:Spp1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.024_bib35","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-pd1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.024_bib36","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to pd-l1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.024_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2567.2011.03429.x","article-title":"The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis","volume":"133","author":"Steding","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2025.03.024_bib38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1620\/tjem.185.223","article-title":"Exogenous recombinant human il-12 augments mhc class i antigen expression on human cancer cells in vitro","volume":"185","author":"Suzuki","year":"1998","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.03.024_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.biomaterials.2016.09.034","article-title":"Polymeric nanoparticles promote macrophage reversal from m2 to m1 phenotypes in the tumor microenvironment","volume":"112","author":"Wang","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2025.03.024_bib40","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.4049\/jimmunol.178.3.1357","article-title":"Il-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo","volume":"178","author":"Watkins","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004561","article-title":"Tumor-targeted interleukin-12 synergizes with entinostat to overcome pd-1\/pd-l1 blockade-resistant tumors harboring mhc-i and apm deficiencies","volume":"10","author":"Minnar","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: Room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.03.024_bib43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cell.2021.01.018","article-title":"Structural basis for il-12 and il-23 receptor sharing reveals a gateway for shaping actions on t versus nk cells","volume":"184","author":"Glassman","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.024_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: Still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2025.03.024_bib45","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.024_bib46","first-page":"1183","article-title":"Phase i trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201706759","article-title":"Cell membrane coating nanotechnology","volume":"30","author":"Fang","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2025.03.024_bib48","doi-asserted-by":"crossref","first-page":"7738","DOI":"10.1021\/acsnano.6b03148","article-title":"Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer","volume":"10","author":"Cao","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2025.03.024_bib49","first-page":"1078","article-title":"Tunneling nanotubular expressways for ultrafast and accurate m1 macrophage delivery of anticancer drugs to metastatic ovarian carcinoma","volume":"13","author":"Guo","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2025.03.024_bib50","first-page":"55","article-title":"Macrophage based drug delivery: Key challenges and strategies","volume":"38","author":"Guo","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.ymthe.2025.03.024_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf5473","article-title":"Cecr2 drives breast cancer metastasis by promoting nf-\u03bab signaling and macrophage-mediated immune suppression","volume":"14","author":"Zhang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.024_bib52","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/0008-5472.CAN-19-2374","article-title":"The immunosuppressive microenvironment in brca1-iris-overexpressing tnbc tumors is induced by bidirectional interaction with tumor-associated macrophages","volume":"80","author":"Sami","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","article-title":"Mct-1\/mir-34a\/il-6\/il-6r signaling axis promotes emt progression, cancer stemness and m2 macrophage polarization in triple-negative breast cancer","volume":"18","author":"Weng","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib54","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib56","doi-asserted-by":"crossref","first-page":"W242","DOI":"10.1093\/nar\/gkab418","article-title":"Gepia2021: Integrating multiple deconvolution-based analysis into gepia","volume":"49","author":"Li","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib57","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13059-016-1028-7","article-title":"Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy","volume":"17","author":"Li","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib58","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"Timer: A web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-pd-1\/pd-l1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chom.2011.07.006","article-title":"Drifting motions of the adenovirus receptor car and immobile integrins initiate virus uncoating and membrane lytic protein exposure","volume":"10","author":"Christoph","year":"2011","journal-title":"Cell Host & Microbe"},{"key":"10.1016\/j.ymthe.2025.03.024_bib61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.024_bib62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107986","article-title":"Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A tam-pting approach","volume":"231","author":"Chamseddine","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.024_bib64","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41568-020-0259-9","article-title":"Macrophages get a car","volume":"20","author":"Villanueva","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib65","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001356","article-title":"Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses","volume":"8","author":"Brempelis","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.024_bib67","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1158\/0008-5472.CAN-10-2349","article-title":"Use of macrophages to target therapeutic adenovirus to human prostate tumors","volume":"71","author":"Muthana","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib68","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.024_bib69","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.omto.2022.04.005","article-title":"Amplification of the cxcr3\/cxcl9 axis via intratumoral electroporation of plasmid cxcl9 synergizes with plasmid il-12 therapy to elicit robust anti-tumor immunity","volume":"25","author":"Lee","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.03.024_bib70","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.immuni.2017.08.002","article-title":"We can still be friends: Ifn-gamma breaks up macrophage enhancers","volume":"47","author":"Novakovic","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.03.024_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113014","article-title":"Crispr-cas9 screening identifies an irf1-socs1-mediated negative feedback loop that limits cxcl9 expression and antitumor immunity","volume":"42","author":"House","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.03.024_bib72","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/2326-6066.CIR-22-0041","article-title":"Treg-dominant tumor microenvironment is responsible for hyperprogressive disease after pd-1 blockade therapy","volume":"10","author":"Wakiyama","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.03.024_bib73","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"Pd-1(+) regulatory t cells amplified by pd-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.024_bib74","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","article-title":"Interruption of the intratumor cd8(+) t cell:Treg crosstalk improves the efficacy of pd-1 immunotherapy","volume":"42","author":"Geels","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.024_bib75","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"Pd-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.024_bib76","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.imlet.2009.08.011","article-title":"Programmed death-1 receptor negatively regulates lps-mediated il-12 production and differentiation of murine macrophage raw264.7 cells","volume":"127","author":"Cho","year":"2009","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ymthe.2025.03.024_bib77","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.ymthe.2021.03.013","article-title":"Inhibition of xct suppresses the efficacy of anti-pd-1\/l1 melanoma treatment through exosomal pd-l1-induced macrophage m2 polarization","volume":"29","author":"Liu","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.024_bib78","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering car-t cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.03.024_bib79","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"Car t cells administered in combination with lymphodepletion and pd-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.024_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121341","article-title":"Il-12 nanochaperone-engineered car t cell for robust tumor-immunotherapy","volume":"281","author":"Luo","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2025.03.024_bib81","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","article-title":"Antigen-dependent il-12 signaling in car t cells promotes regional to systemic disease targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.024_bib82","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral il-12 delivery empowers car-t cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.024_bib83","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00262-022-03193-6","article-title":"Cxcl9-modified car t cells improve immune cell infiltration and antitumor efficacy","volume":"71","author":"Tian","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2025.03.024_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered car-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:11:45Z","timestamp":1782958305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625001984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1525001625001984"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.024","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}